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In this respect, in this CTMC thematic issue, Dr Jones evaluated novel and 
exciting developments in triblock, graft and hyperbranched polymer chemistries that 
are changing the way polymeric micelles drug formulations are engineered. The 
issue continues with Prof Antimisiaris evaluating the characteristics of 
nanoliposomes functionalized with three different ligands that are critical for reversal 
of Aβ-induced cytotoxicity and their ability to inhibit Aβ peptide aggregation for their 
potential to target one of the main pathologies of Alzheimer’s disease, the amyloid 
plaques. As there is an increased interest in non-spherical nanomedicines, the issue 
discusses peptide amphiphile (polypeptide block copolymers) architecture 
fundamentals that govern the self-assembly of peptide amphiphiles into spherical but 
mostly high axial nanostructures for range of application ranging from permeation 
across the BBB and cancer to regenerative medicine. On this note, Ruso’s et al 
discuss inorganic hierarchically materials and their application in the field of 
orthopaedic regenerative medicine, while Dr Baeza and Prof Vallet-Regi discuss the 
current state of mesoporous silica nanocarriers as anti-tumour therapies. The issue 
finishes presenting current advances in “bottom-up” and “top-down” fabrication 
techniques for the preparation of nanomedicines such as electrohydrodynamic 
preparation and nanonisation technologies respectively.  
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Improving the therapeutic index of medicines is a perpetual 
goal of both medicinal chemists and drug delivery scientists. 
Nanomedicine, the application nanotechnology to medicine, works 
at the molecular level using “bottom up” or with advent of novel 
fabrication methods “top down” constructed multifunactional, 
spatially ordered architecturally varied nanostructures to ultimately 
improve bioavailability and targeting achieving medical benefit. This 
field possesses an interdisciplinary conceptual breadth bringing 
together scientists and clinicians towards the engineering of useful 
architectures made up of individual building blocks driven by 
discrete molecular forces (chemical bonding, electrostatics, steric 
interactions and physical adsorption) aimed to be clinically 
translated as multifunctional, often biomimetic and bioresponsive 
systems. This issue presents a series of contributions on current 
advances in understanding the engineering and fabrication of 
organic or inorganic nanomedicines for a variety of applications in 
drug delivery across challenging barriers such as the blood-brain 
barrier (BBB) and to intracellular targets, regenerative medicines 
and cancer.  
 
 
 
is rapidly moving from the development of individual building 
blocks to multifunctional, often biomimetic and bioresponsive 
systems.  
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